DOT-EPR-Header

One of the most recent and exciting areas of discovery research centers around targeting chromatin modifying proteins, particularly those responsible for the recognition of the histone code written in acetyl and methyl marks. With several clinical trials underway, and discovery programs initiated throughout the biopharma landscape, particular interest has been given to targeting the bromodomain family of proteins across a diverse range of therapeutic indications. Advances in inhibitor development - allowing for individual and polypharmacological targeting of bromodomain proteins, as well as preclinical and clinical studies, are providing a better understanding as to the significant therapeutic potential of targeting chromatin-associated proteins.>

Cambridge Healthtech Institute's third annual Targeting Epigenetic Readers and Chromatin Remodelers meeting will once again unite academic and industry researchers for the development of chemical probes, to discuss advances in preclinical and clinical programs, and ultimately to further our understanding of the therapeutic opportunities associated with targeting reader domains and chromatin remodelers.

Preliminary Agenda


DEVELOPING NOVEL BROMODOMAIN INHIBITORS

 

New Chemical Tools Targeting BET Bromodomains and Advances in the Bump and Hole Approach 

Alessio Ciulli, Ph.D., Associate Professor & Principal Investigator, Chemical & Structural Biology, College of Life Sciences, University of Dundee

Discovery of PFI-4: A New Probe for the Bromodomain BRPF1 

Dafydd Owen, Ph.D., Associate Research Fellow, Medicinal Chemistry, Biotherapeutics Worldwide R&D, Pfizer

Targeting Gene Expression: Selective vs. Promiscuous Bromodomain Inhibition

Panagis Filippakopoulos, Ph.D., Principal Investigator, Bromodomains, Structural Genomics Consortium & Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford

Design and Development of Novel BET Bromodomain Inhibitors

Shaomeng Wang, Ph.D., Director, Center for Discovery of New Medicines; Warner-Lambert/Parke-Davis Professor, Medicine, Pharmacology and Medicinal Chemistry, University of Michigan Comprehensive Cancer Center


EVALUATING THERAPEUTIC POTENTIAL

Preclinical Activity of a Novel BET Bromodomain Inhibitor

Phillip Liu, Ph.D., Associate Directory, Applied Technology, Incyte Corporation

Efficacy of BET Bromodomain Inhibition in Hematological Tumor Models

Bernard Haendler, Ph.D., Principal Scientist, Global Drug Discovery, Bayer Pharma AG


CLINICAL DEVELOPMENT

CPI-0610: A Novel BET Protein Bromodomain Inhibitor for Hematologic Malignancies

Robert J. Sims III, Ph.D., Executive Director, Biology, Constellation Pharmaceuticals, Inc.

Inhibition of BET Bromodomain Proteins in Cancer Treatment

Ryan Kruger, Ph.D., Director, Discovery Biology, GlaxoSmithKline

RVX-208, a First in Class Compound to Enter into Clinical Development

Norman C.W. Wong, M.D., FRCP, CSO & Co-Founder, Resverlogix



For questions or suggestions about the meeting, please contact:
Kip Harry
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5454
E: kharry@healthtech.com 

For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Jon Stroup
Sr. Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

DOT Hub Icon

2014 Discovery on Target Brochure  


IPR_Micrombiome 


2014 BROCHURE 

 PREMIER SPONSORS 

Cellecta 

Molecular Sensing 

Rosa Drug Development Advisors
 

VIEW ALL SPONSORS 

VIEW MEDIA PARTNERS 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2014, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Jon Stroup
Sr. Business Development Manager
781-972-5483
jstroup@healthtech.com 


Westin Boston Waterfront

HOTEL & TRAVEL 

Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
617.426.2000